Blog

Blog

Ipilimumab: The First Checkpoint Inhibitor
Ipilimumab: The First Checkpoint Inhibitor

The immune system plays a critical role in identifying and eliminating cancer cells. However, tumors can evade immune detection by exploiting immune checkpoints, which are molecular brakes that prevent excessive immune activation. One of the key checkpoints is cytotoxic T-lymphocyte-

Feb 14, 2025
Read time: 10 mins
Blinatumomab: The First Bispecific Antibody in Oncology
Blinatumomab: The First Bispecific Antibody in Oncology

Bispecific antibodies (BsAbs) represent a major advancement in immunotherapy by enabling the simultaneous targeting of two different antigens. Blinatumomab (Blincyto, Amgen) was the first bispecific T-cell engager (BiTE) antibody approved for oncology, marking a significant breakthrough in the treatment of B-cell malignancies. This article reviews the development, mechanism of action, clinical efficacy, and impact of blinatumomab on the evolving landscape of targeted cancer therapies.

Feb 13, 2025
Read time: 10 mins
Gemtuzumab Ozogamicin: The First Approved ADC
Gemtuzumab Ozogamicin: The First Approved ADC

The development of antibody-drug conjugates (ADCs) has transformed cancer treatment by combining the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy agents. Gemtuzumab ozogamicin (GO) was the first ADC to receive FDA approval, marking a significant milestone in targeted oncology therapies. Initially approved in 2000 for relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn in 2010 due to safety concerns.

Feb 12, 2025
Read time: 8 mins
Pivotal Moments in Oncology Antibody Drug Development
Pivotal Moments in Oncology Antibody Drug Development

The past 25 years have seen significant advancements in therapeutic antibodies for cancer treatment, driven by academic and industrial collaborations. From the approval of rituximab in 1997 to the development of immune checkpoint inhibitors and bispecific antibodies, oncology has witnessed a transformation in drug discovery and regulatory approvals.

Feb 11, 2025
Read time: 9 mins
Bispecific Antibodies in Cancer Therapy: Engineering, Mechanisms, and Clinical Applications
Bispecific Antibodies in Cancer Therapy: Engineering, Mechanisms, and Clinical Applications

Bispecific antibodies (bsAbs) represent an important advancement in cancer immunotherapy, enabling dual-targeting mechanisms that enhance tumor specificity, immune activation, and therapeutic efficacy. The structural and functional versatility of bsAbs allows for diverse formats tailored to different clinical needs.

Feb 10, 2025
Read time: 8 mins
Antibodies to Watch in 2025: Recent Developments in Antibody Therapeutics
Antibodies to Watch in 2025: Recent Developments in Antibody Therapeutics

Antibody-based therapies continue to play a pivotal role in the treatment of autoimmune diseases, infectious diseases, and cancer. Recent regulatory advancements highlight the progress of multiple investigational and approved therapies across various indications.

Feb 07, 2025
Read time: 6 mins
Future Directions for VHH Antibody Research and Development
Future Directions for VHH Antibody Research and Development

VHH antibodies, also known as nanobodies, have emerged as a transformative class of biologics with applications spanning oncology, neurology, and targeted drug delivery. Their small size, high stability, and unique binding properties allow them to overcome many limitations of conventional monoclonal antibodies (mAbs).

Feb 06, 2025
Read time: 7 mins
Monoclonal Antibodies: Evolution, Therapeutic Applications, and Future Directions
Monoclonal Antibodies: Evolution, Therapeutic Applications, and Future Directions

DOI: 10.3389/fimmu.2019.01598Monoclonal antibodies (mAbs) have transformed modern medicine by providing highly specific therapies for cancer, autoimmune diseases, and infectious diseases. Their development traces back to key immunological discoveries that laid the groundwork for antibody-based thera

Feb 05, 2025
Read time: 8 mins
Applications of Bispecific Antibodies in Therapeutics
Applications of Bispecific Antibodies in Therapeutics

Bispecific antibodies (bsAbs) represent a significant advancement in therapeutic antibody technology, simultaneously binding to two different antigens to enable novel treatment mechanisms across multiple disease areas, including oncology, hematology, ophthalmology, and diagnostics.

Feb 04, 2025
Read time: 10 mins
5 Key Facts About IgG Antibodies
5 Key Facts About IgG Antibodies

Immunoglobulin G (IgG) antibodies are an essential part of the immune system, defending against infections and maintaining immune memory. These antibodies recognize and neutralize pathogens, providing long-term immunity after infection or vaccination. Beyond their biological role, IgG antibodies are widely used in biomedical research, diagnostics, and therapeutic applications.

Feb 03, 2025
Read time: 8 mins
Hosts for Recombinant mAb Production
Hosts for Recombinant mAb Production

Monoclonal antibodies (mAbs) are the largest class of recombinant proteins used as therapeutics, playing a critical role in treating cancers, autoimmune diseases, and infectious conditions. Producing recombinant mAbs requires a host system that can efficiently express, fold, and modify these complex proteins while maintaining their efficacy and safety.

Jan 31, 2025
Read time: 9 mins
Monoclonal Antibody Therapeutics Production in Four Eras
Monoclonal Antibody Therapeutics Production in Four Eras

The development of monoclonal antibody (mAb) therapeutics began in 1975 when Köhler and Milstein developed hybridoma technology, a breakthrough that earned them the Nobel Prize in 1984. The first mAb approved for human use, Orthoclone OKT3 (muromonab-CD3), was licensed in 1986 for preventing kidney transplant rejection.

Jan 30, 2025
Read time: 6 mins

Keep yourself updated with Biointron Insights

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.